Chiesi Group account plan
Biopharma, BCorp, Global, Research
At a glance
Chiesi Group is a family-owned Parma pharmaceutical group in respiratory, rare diseases and specialty care, with FY2025 revenues of €3,625M.
Chiesi Group is a family-owned, research-focused pharmaceutical group founded in 1935 and headquartered in Parma, Italy, controlled through Valline S.r.l. It develops and sells medicines in three business areas: Air (respiratory), Rare (rare and ultra-rare diseases) and Care (neonatology, transplant, cardiovascular and consumer healthcare), through 31 affiliates, 4 production plants and 7 R&D centres. FY2025 consolidated revenues were €3,625M (+8.2% at constant exchange rates), with EBITDA of €931M (25.7% of revenues) and record R&D investment of €885M. The group had 7,934 employees at end-2025 and is a Benefit Corporation and certified B Corp; Jean-Marc Bellemin is CFO and Interim Group CEO.
Business units
Air (respiratory health)
about 52% of FY2025 revenues (€1,886M)Inhaled treatments for asthma, COPD, idiopathic pulmonary fibrosis, bronchiectasis and pulmonary arterial hypertension, with Foster, Trimbow and Clenil as main products. Revenue grew 3.9% at CER in 2025, driven by 15.8% growth of the triple inhaled therapy against generic competition on legacy products; in H1 2026 respiratory was broadly stable (-0.8% @CER). The Carbon Minimal Inhaler programme moves pMDIs to a low-GWP propellant.
Care (specialty care)
about 25% of FY2025 revenues (€904M)Products for neonatal respiratory distress, apnea of premature newborns, solid organ transplant, acute and cardiovascular diseases and consumer healthcare, including Curosurf, Kengreal, Envarsus, Cleviprex and Peyona. Revenue grew 13.3% at CER in 2025 and neonatology and specialty care grew 6.5% @CER in H1 2026.
Rare (Chiesi Global Rare Diseases)
about 23% of FY2025 revenues (€835M)Treatments for inborn defects of metabolism, rare haematologic and immunologic diseases, endo-metabolic disorders and dermatology, including Myalept, Revcovi, Elfabrio and Ferriprox. Based in Boston and expanded by the Amryt Pharma acquisition, it was the main growth engine in H1 2026 (+9.9% @CER) and added KalVista Pharmaceuticals' oral HAE treatment.
Strategic priorities
- €6 billion of sales by 2030
- Chiesi aims to reach €6 billion of sales by 2030, with around 10-15% of the goal from acquisitions in respiratory, specialty pharma and rare diseases.
- Grow rare diseases and the U.S.
- Rare diseases and the United States drive growth: the U.S. grew 28.9% at CER in 2025 and 9.6% @CER in H1 2026.
- Carbon Minimal Inhaler rollout
- Move six pMDI formulations to the low-GWP, non-PFAS propellant HFA 152a, cutting product footprint by up to 90%, with a Bespak partnership to deliver CMIs at scale.
- Climate targets
- SBTi targets of a 90% cut in Scope 1 and 2 emissions by 2030 and a 90% cut in key Scope 3 categories by 2035, both against 2019.
- Mid-single-digit growth in 2026
- The 2026 outlook is mid-single-digit revenue growth, with late-stage respiratory programmes and low-GWP propellant pMDI launches.
Latest results
In H1 2026 (six months to 30 June) revenues were €1.89 billion, up 3.6% at constant exchange rates excluding the KalVista acquisition, slower than the 8.2% growth of FY2025. Rare diseases grew 9.9% @CER, neonatology and specialty care 6.5% and respiratory was broadly stable at -0.8%. By region the United States grew 9.6% @CER, Europe 0.9% and remaining geographies 5.5%. The EBITDA margin was 29.4% and R&D investment €426 million, about 22.5% of revenues.
Investments and deals
- KalVista Pharmaceuticals acquisition
- Completed in H1 2026, adding an oral on-demand treatment for hereditary angioedema and expanding the U.S. presence.
- Nerviano site
- Industrial site near Milan acquired in March 2025 and being redeveloped for sterile biologics and carbon-minimal inhalers.
- Biotech Center of Excellence in Parma
- A €400M investment inaugurated in 2024, integrating the full biologics production process.
- Rare disease partnerships
- Three 2025 partnerships with Key2Brain, Arbor Biotechnologies and Aliada Therapeutics on brain-penetrating enzyme therapies and gene editing.
- Record R&D
- R&D investment of €885M in FY2025, 24.4% of revenues.
Challenges and risks
- Slowing growth and flat Europe
- H1 2026 growth slowed to 3.6% @CER, with Europe at +0.9% and EU Top5 markets broadly stable in 2025.
- Generics on legacy respiratory products
- Continued generic competition on legacy respiratory products is offset only by growth of the triple inhaled therapy.
- Inhaler propellant regulation
- Regulatory pressure on high-GWP inhaler propellants and a market shift to dry powder and soft mist inhalers are the key climate risk.
- Supply chain dependence
- Dependence on direct suppliers and external manufacturers can cause shortages, delays and quality issues affecting critical therapies.
- CEO transition and U.S. tariffs
- CEO Giuseppe Accogli left on 15 May 2026 and a permanent successor is being sought; U.S. tariffs may eventually require U.S. manufacturing.
What leadership says
“the acquisition of KalVista further strengthens our position in rare diseases and expands our presence in the U.S.”
“We are looking in respiratory, in specialty pharma and in rare diseases, not only in Italy, but also globally.”
“reflect the resilience of our strategy and the strength of our global footprint”
Where a supplier can help
- Inhaler manufacturing and propellant transition
- The Carbon Minimal Inhaler rollout and Nerviano redevelopment need device, filling-line and engineering suppliers.
- U.S. rare disease commercial build-out
- U.S. growth and the KalVista integration call for patient support, market access and CRM providers in rare diseases.
- Supply chain resilience
- Supply chain dependence on external manufacturers creates demand for supplier risk monitoring, CMOs and inventory planning tools.
- Emissions reduction across the value chain
- The 2030 and 2035 SBTi targets push Chiesi to work with vendors on CO2 reduction, opening doors for energy, logistics and carbon accounting suppliers.
- Clinical development support
- Record R&D and late-stage respiratory programmes create demand for CROs and clinical data services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Chiesi Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Chiesi Group Sustainability Report 2025 (group annual report)
- Chiesi Group is a family-owned, Parma-headquartered research-focused pharmaceutical group (founded 1935) organised in three business areas, Air (respiratory), Rare (rare and ultra-rare diseases) and Care (neonatology, transplant, cardiovascular, consumer healthcare); 31 affiliates, 4 production plants and 7 R&D centres; parent company Valline S.r.l.
- FY2025 consolidated revenues €3,625M (2024: €3,413M), +8.2% at constant exchange rates; EBITDA €931M, 25.7% of revenues (2024: €1,004M, 29.4%).
- By business area: Air €1,886M (+3.9% @CER), Care €904M (+13.3%), Rare €835M (+13.0%); Trimbow, the fixed triple combination for asthma and COPD, "contributed considerably" to 2025 growth.
- Record R&D investment of €885M, 24.4% of revenues (2024: €829M, 24.3%); 6,324 patents in the portfolio and 36 first filings at the EPO; 1st among Italian pharmaceutical companies in the EU Industrial R&D Investment Scoreboard.
- Workforce of 8,081 (7,732 internal employees plus 349 external collaborators): Italy 32.7%, rest of Europe 34.4%, North America 25.1%, rest of world 7.8%.
- Economic value generated €3,662M, of which €3,012M (about 82%) distributed (suppliers €1,850M, employees €874M) and €650M retained to self-finance innovation.
- Industrial investments: €400M Biotech Center of Excellence in Parma (opened 2024); new Nerviano site (near Milan) acquired in March 2025 for inhalers and biologics.
- Carbon Minimal Inhaler programme: six pMDI formulations moving to the low-GWP, non-PFAS propellant HFA 152a, cutting product footprint by up to 90%; phase III safety study for the fixed triple completed and the beclomethasone CMI pMDI submitted to the UK MHRA at end-2025. SBTi targets: -90% Scope 1-2 by 2030 and -90% for key Scope 3 categories by 2035 vs 2019.
- Governance: Benefit Corporation (Italy, US, France, Colombia), third B Corp certification in 2025 with a score of 117.5; three independent non-executive directors (Roch Doliveux, Paolo Pucci, Daphne Quimi) joined the Board in January 2025, which set up three Board committees.
- Key risks named: supply chain and own-plant disruptions affecting critical therapies, REACH / substances-of-concern regulation, regulatory pressure on high-GWP inhaler propellants and the market shift to dry-powder and soft-mist inhalers, cybersecurity.
- Chiesi Group delivers solid H1 2026 performance (H1 2026 results release)
- H1 2026 revenues €1.89 billion, +3.6% at CER vs H1 2025, excluding the KalVista acquisition.
- Rare diseases grew +€45m (+9.9% @CER); neonatology and specialty care +6.5% @CER; respiratory broadly stable (-0.8% @CER) with strong growth of the inhaled triple therapy portfolio.
- By region: United States +9.6% @CER, Europe +0.9%, remaining geographies +5.5%.
- EBITDA margin 29.4%; solid operating cash generation funds pipeline, manufacturing and acquisitions.
- R&D investment €426 million, about 22.5% of revenues, including the Carbon Minimal Inhaler platform and a strategic partnership with Bespak to deliver CMIs at scale.
- Completed the acquisition of KalVista Pharmaceuticals (US), adding an oral on-demand treatment for hereditary angioedema (HAE) to the rare disease platform.
- PwC Italy economic footprint study (2025): about €6 billion of GDP, 56,488 jobs and nearly €2 billion in taxes worldwide; Europe €4.1 billion GDP and 78% of global R&D investment.
- Jean Marc Bellemin is CFO and Interim CEO.
- Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition
- FY2025 consolidated revenues €3.625 billion, +8.2% at CER; EBITDA €931 million (25.7%).
- Positive net financial position of €729 million (cash minus financial liabilities including leasing), up €194 million vs 2024.
- Rare sales €906 million (+22.3% at CER), representing 50% of total group growth; Air €1.886 billion (+3.9%) with the triple inhaled therapy up 15.8%; Care €904 million (+13.3%).
- US fastest-growing region (+28.9% at CER); EU midsize countries +9.8%; EU Top5 broadly stable (-0.6%).
- Record R&D investment of €885 million (24.4% of revenues); three rare disease partnerships in 2025 (Key2Brain, Arbor Biotechnologies, Aliada Therapeutics).
- CEO Giuseppe Accogli leaves on 15 May 2026; Group CFO Jean-Marc Bellemin named Interim Group CEO while a search is underway.
- 2026 outlook: mid-single-digit revenue growth; late-stage respiratory programmes and low-GWP propellant pMDI launches.
- Scope 1 and 2 emissions down 56% vs 2019; EcoVadis Platinum (88/100); 7,934 employees after 392 new roles.
- Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030 (Reuters interview)
- Chiesi aims to reach €6 billion of sales by 2030 (doubling) and to significantly increase the number of patients treated from around 10 million.
- Acquisitions are part of the plan: around 10-15% of the sales goal should come from inorganic opportunities being scouted.
- Target areas for M&A: respiratory, specialty pharma and rare diseases, in Italy and globally; "no rush".
- Chiesi has no debt and earns around €1 billion of EBITDA a year, giving "firepower" to reach €5-6 billion of sales with its own resources.
- Declined to comment on any approach to listed Italian rival Recordati: "we always look at everything that is available".
- 2025 expected revenue growth of more than mid-single digit, after 13% growth in 2024 to €3.4 billion.
- US tariffs described as "still very confused"; a US manufacturing presence may eventually be needed to complement sites in France, Italy and Brazil, but nothing concrete is planned.
Questions about Chiesi Group
What does Chiesi Group do?
Chiesi is a family-owned pharmaceutical group from Parma that develops and sells medicines for respiratory health, rare diseases and specialty care such as neonatology and transplant.
What is Chiesi's revenue?
FY2025 consolidated revenues were €3,625M, up 8.2% at constant exchange rates, with EBITDA of €931M. H1 2026 revenues were €1.89 billion.
How many employees does Chiesi have?
Chiesi had 7,934 employees at the end of 2025, after creating 392 new roles.
Who leads Chiesi Group?
Alessandro Chiesi is Chairperson. Jean-Marc Bellemin is Group CFO and Interim Group CEO since Giuseppe Accogli left on 15 May 2026.
What is Chiesi's strategy?
Chiesi aims to reach €6 billion of sales by 2030 through growth in rare diseases, the U.S. and acquisitions, while moving its inhalers to a low-GWP propellant.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)